Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II Study

NCT06093841 is registered in ClinicalTrials.gov with Shanghai Ming Ju Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06093841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06093841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II Study
Lead sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 3, 2023
Completion date
November 4, 2029
Enrollment
46 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma grade 3b, high-grade b-cell lymphoma, lymphoma, large b-cell, diffuse, mediastinal b-cell diffuse large cell lymphoma